Filing Flows › Tandem Diabetes Care (TNDM) › R&D spending
Tandem Diabetes Care (TNDM) R&D spending by quarter
Tandem Diabetes Care's R&D spending was $48.8M in Q3 2026 (third quarter 2026), +4% from Q2 2026. Over the last 7 quarters it ranged from $46.0M (Q1 2026) to $50.2M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $48.8M | +4% | +0.3% |
| Q2 2026 | $46.9M | +2% | -2% |
| Q1 2026 | $46.0M | -0.1% | -8% |
| Q4 2025 | $46.1M | -5% | — |
| Q3 2025 | $48.7M | +1% | — |
| Q2 2025 | $48.1M | -4% | — |
| Q1 2025 | $50.2M | — | — |
Q3 2026 at a glance
Tandem Diabetes Care, Q3 2026: revenue $284M (+14% year over year), operating margin -0.8%, net loss $7.1M, operating cash flow −$819K. The chart follows the revenue to costs, profit and cash.
Questions
What is Tandem Diabetes Care's R&D spending?
Tandem Diabetes Care's R&D spending was $48.8M in Q3 2026 (third quarter 2026), +4% from Q2 2026.
How has Tandem Diabetes Care's R&D spending changed?
Over the last 7 quarters it ranged from $46.0M (Q1 2026) to $50.2M (Q1 2025).